^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PD-L1 (Programmed death ligand 1)

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    1d
    Neuroblastoma Precision Trial (clinicaltrials.gov)
    P=N/A, N=93, Active, not recruiting, New Approaches to Neuroblastoma Therapy Consortium | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    1d
    Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant (clinicaltrials.gov)
    P4, N=40, Recruiting, Icahn School of Medicine at Mount Sinai | Initiation date: Jan 2026 --> Jun 2026
    Trial initiation date
    |
    PD-L1 (Programmed death ligand 1) • AFP (Alpha-fetoprotein) • CD4 (CD4 Molecule)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • oxaliplatin • irinotecan
    1d
    NCI-2018-00192: Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, Dwight Owen | N=30 --> 9 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • sunitinib
    1d
    INDIGO: Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures (clinicaltrials.gov)
    P2, N=0, Withdrawn, Gustave Roussy, Cancer Campus, Grand Paris | N=115 --> 0 | Trial completion date: Jan 2030 --> Sep 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jan 2028 --> Sep 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    2d
    Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Pfizer
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    2d
    A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=120, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    4d
    CHANCES: A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=27, Recruiting, Institut Paoli-Calmettes | Trial completion date: Feb 2026 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset)
    |
    PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 expression • BRCA mutation • PD-L1 expression + HER-2 overexpression
    |
    Herceptin (trastuzumab) • paclitaxel • IPH5301
    4d
    Magnetic Resonance Imaging of the Lung: Oncological Applications (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Fondazione IRCCS Policlinico San Matteo di Pavia
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    4d
    Precision: Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib (clinicaltrials.gov)
    P1/2, N=53, Not yet recruiting, Shanxi Province Cancer Hospital
    New P1/2 trial • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule)
    |
    EGFR mutation • PIK3CA mutation • EGFR L858R • EGFR exon 19 deletion • AKT1 mutation
    |
    Tagrisso (osimertinib) • Truqap (capivasertib)
    4d
    Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy (clinicaltrials.gov)
    P2, N=39, Completed, UNC Lineberger Comprehensive Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine
    4d
    POST-BIO: Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC) (clinicaltrials.gov)
    P2, N=45, Recruiting, Gruppo Oncologico del Nord-Ovest
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    4d
    Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases (clinicaltrials.gov)
    P=N/A, N=770, Active, not recruiting, Brigham and Women's Hospital
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel